Study Objectives: There is contradictory evidence on whether sleep need decreases across adolescence. We investigated this question longitudinally with a dose-response design to test the effects of varied sleep durations on daytime sleepiness and on vigilance and to test whether these relations change with age across early and mid-adolescence.

Methods: Data from 76 participants who completed at least 2 years of the 3-year study are included in this report. Annually, participants ranging in age from 9.8 to 16.2 years completed three different time in bed (TIB) schedules each consisting of four consecutive nights of 7, 8.5, or 10 hours. Daytime sleepiness (multiple sleep latency test [MSLT]) and vigilance (psychomotor vigilance test [PVT]) were measured on the day following the fourth night of each TIB schedule.

Results: Electroencephalogram (EEG)-measured sleep durations changed linearly with TIB. MSLT-measured daytime sleepiness decreased with longer TIB and increased with age. The TIB and age effects interacted such that the TIB effect decreased with age. PVT performance improved with longer TIB and improved with age, but the benefit that increased TIB conferred on PVT performance did not change with age.

Conclusions: These results seem paradoxical because daytime sleepiness increased but vigilance improved with age. The significant age effect on the relation between TIB and sleepiness compared to the lack of an age effect on the relation between TIB and vigilance performance suggests different rates of maturation in underlying brain systems. We interpret these findings in relation to our model of adolescent brain development driven by synaptic elimination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191880PMC
http://dx.doi.org/10.1093/sleep/zsy177DOI Listing

Publication Analysis

Top Keywords

daytime sleepiness
20
age
10
tib
10
sleepiness vigilance
8
sleep durations
8
vigilance test
8
longer tib
8
pvt performance
8
improved age
8
age relation
8

Similar Publications

Background And Objective: Non-motor symptoms frequently develop throughout the disease course of Parkinson's disease (PD), and pose affected individuals at risk of complications, more rapid disease progression and poorer quality of life. Addressing such symptom burden, the 2023 revised "Parkinson's disease" guideline of the German Society of Neurology aimed at providing evidence-based recommendations for managing PD non-motor symptoms, including autonomic failure, pain and sleep disturbances.

Methods: Key PICO (Patient, Intervention, Comparison, Outcome) questions were formulated by the steering committee and refined by the assigned authors.

View Article and Find Full Text PDF

Background: Sleep dysfunction is commonly seen in Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP), potentially worsening these conditions. Investigating early neuropathological changes in human sleep-promoting neurons, which often precede cognitive decline, is crucial for understanding the basis for sleep dysfunction as possible treatments yet remain underexplored. We used postmortem brains of AD and PSP patients to quantify neuronal numbers and tau burden in the intermediate nucleus of the hypothalamus (IntN), VLPO analog, known for its role in sleep maintenance.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Physiopathology in Aging Laboratory (LIM-22), University of São Paulo Medical School, São Paulo, São Paulo, Brazil.

Background: Excessive daytime sleepiness is a common and early symptom of Alzheimer's disease (AD). The subcortical wake-promoting neurons in the lateral hypothalamic area, tuberomammillary nucleus (TMN), and locus coeruleus synchronize to maintain wakefulness/arousal. Although significant neuronal decline occurs in wake-promoting regions, the TMN histaminergic neurons remain relatively more intact than orexinergic and nor-adrenergic neurons.

View Article and Find Full Text PDF

Sleep disturbances, such as insomnia, are associated with Alzheimer's disease pathology and future risk of cognitive impairment. This raises the exciting possibility of repurposing existing drugs to prevent or delay Alzheimer's disease since there are multiple drug approved by the Food and Drug Administration for the treatment of insomnia. Dual orexin receptor antagonists (DORAs) are one such class of medications.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.

Background: Changes in sleep are common in older persons and have been linked to higher dementia risk. The link between sleep complaints and early risk markers of Alzheimer's disease (AD), namely subjective changes in cognition and mild behavioral impairment (MBI), have not been fully explored. This study investigated associations between sleep complaints with cognitive and behavioral AD risk markers and quality of life (QoL) among cognitively unimpaired older persons.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!